PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia
- Conditions
- Community-Acquired Pneumonia (CAP)
- Interventions
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 219
- Registration Number
- NCT00035347
- Locations
- 🇪🇸
Pfizer Investigational Site, Tarrasa, Cataluna, Spain
Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2009-12-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 120
- Registration Number
- NCT00035425
- Locations
Pfizer Investigational Site
Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)
- Conditions
- Carcinoma, Non-Small-Cell LungLung Neoplasms
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2012-02-16
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00034957
- Locations
- 🇺🇸
Research Center, Dallas, Texas, United States
New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)
- Conditions
- Pneumonia, PneumococcalCommunity Acquired InfectionsGram-positive Bacterial Infections
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2011-04-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 230
- Registration Number
- NCT00035269
- Locations
- 🇨🇳
Research Center, Taoyuan, Taiwan
A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer
- Conditions
- Colorectal NeoplasmsBreast NeoplasmsCarcinoma, Non-Small-Cell LungPancreatic Neoplasms
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2007-05-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 172
- Registration Number
- NCT00034827
- Locations
- 🇺🇸
Pfizer Investigational Site, Cincinnati, Ohio, United States
Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer
- First Posted Date
- 2002-03-01
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00031278
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Fletcher Allen Health Care, Burlington, Vermont, United States
🇺🇸Univ. of Connecticut Health Center, Farmington, Connecticut, United States
An Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis
- Conditions
- Meningitis, CryptococcalHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002077
- Locations
- 🇺🇸
Cook County Hosp, Chicago, Illinois, United States
🇺🇸Saint Michael's Med Ctr, Newark, New Jersey, United States
🇺🇸Cabrini Med Ctr, New York, New York, United States
A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients With AIDS
- Conditions
- Meningitis, CryptococcalHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002294
- Locations
- 🇺🇸
UCI Med Ctr, Orange, California, United States
🇺🇸Dr Robert Larsen, Los Angeles, California, United States
🇺🇸UCSD, San Diego, California, United States
Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS
- Conditions
- Meningitis, CryptococcalHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 330
- Registration Number
- NCT00001017
- Locations
- 🇺🇸
Beth Israel Deaconess - West Campus, Boston, Massachusetts, United States
🇺🇸SUNY - Stony Brook, Stony Brook, New York, United States
🇺🇸Duke Univ Med Ctr, Durham, North Carolina, United States
A Study of Azithromycin in HIV-Infected Patients
- Conditions
- Bacterial InfectionsHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00002344
- Locations
- 🇺🇸
Harris Laboratories Inc, Phoenix, Arizona, United States